131 related articles for article (PubMed ID: 37677989)
21. Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma.
Abou-Alfa GK; Puig O; Daniele B; Kudo M; Merle P; Park JW; Ross P; Peron JM; Ebert O; Chan S; Poon TP; Colombo M; Okusaka T; Ryoo BY; Minguez B; Tanaka T; Ohtomo T; Ukrainskyj S; Boisserie F; Rutman O; Chen YC; Xu C; Shochat E; Jukofsky L; Reis B; Chen G; Di Laurenzio L; Lee R; Yen CJ
J Hepatol; 2016 Aug; 65(2):289-95. PubMed ID: 27085251
[TBL] [Abstract][Full Text] [Related]
22. Novel low-avidity glypican-3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC.
Caraballo Galva LD; Jiang X; Hussein MS; Zhang H; Mao R; Brody P; Peng Y; He AR; Kehinde-Ige M; Sadek R; Qiu X; Shi H; He Y
Hepatology; 2022 Aug; 76(2):330-344. PubMed ID: 34897774
[TBL] [Abstract][Full Text] [Related]
23. A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma.
Wu Q; Pi L; Le Trinh T; Zuo C; Xia M; Jiao Y; Hou Z; Jo S; Puszyk W; Pham K; Nelson DR; Robertson K; Ostrov D; Rameshwar P; Xia CQ; Liu C
Mol Ther; 2017 Oct; 25(10):2299-2308. PubMed ID: 28865999
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma.
Zaghloul RA; El-Shishtawy MM; El Galil KH; Ebrahim MA; Metwaly AA; Al-Gayyar MM
Eur J Pharmacol; 2015 Jan; 746():353-62. PubMed ID: 25449037
[TBL] [Abstract][Full Text] [Related]
25. [The cancer specific antigen, glypican-3 (GPC3)-targeted immunotherapy].
Sawada Y; Nakatsura T
Nihon Rinsho; 2012 Dec; 70(12):2136-41. PubMed ID: 23259386
[TBL] [Abstract][Full Text] [Related]
26. Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma.
Yu M; Luo H; Fan M; Wu X; Shi B; Di S; Liu Y; Pan Z; Jiang H; Li Z
Mol Ther; 2018 Feb; 26(2):366-378. PubMed ID: 29339014
[TBL] [Abstract][Full Text] [Related]
27. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment.
Zhou F; Shang W; Yu X; Tian J
Med Res Rev; 2018 Mar; 38(2):741-767. PubMed ID: 28621802
[TBL] [Abstract][Full Text] [Related]
28. Combining expression of GPC3 in tumors and CD16 on NK cells from peripheral blood to identify patients responding to codrituzumab.
Chen G; Chen YC; Reis B; Belousov A; Jukofsky L; Rossin C; Muehlig A; Xu C; Essioux L; Ohtomo T; Di Laurenzio L; Puig O; Lee R
Oncotarget; 2018 Feb; 9(12):10436-10444. PubMed ID: 29535817
[TBL] [Abstract][Full Text] [Related]
29. Radiofluorinated GPC3-Binding Peptides for PET Imaging of Hepatocellular Carcinoma.
Li Y; Zhang J; Gu J; Hu K; Huang S; Conti PS; Wu H; Chen K
Mol Imaging Biol; 2020 Feb; 22(1):134-143. PubMed ID: 31044341
[TBL] [Abstract][Full Text] [Related]
30. Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy.
Gao W; Kim H; Feng M; Phung Y; Xavier CP; Rubin JS; Ho M
Hepatology; 2014 Aug; 60(2):576-87. PubMed ID: 24492943
[TBL] [Abstract][Full Text] [Related]
31. Development of a Tetravalent T-Cell Engaging Bispecific Antibody Against Glypican-3 for Hepatocellular Carcinoma.
Yu L; Huang N; Sun H; Yang X; Fu Y; Lang Q; Wang J; Ge L
J Immunother; 2021 Apr; 44(3):106-113. PubMed ID: 33239522
[TBL] [Abstract][Full Text] [Related]
32. Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer.
Ishiguro T; Sugimoto M; Kinoshita Y; Miyazaki Y; Nakano K; Tsunoda H; Sugo I; Ohizumi I; Aburatani H; Hamakubo T; Kodama T; Tsuchiya M; Yamada-Okabe H
Cancer Res; 2008 Dec; 68(23):9832-8. PubMed ID: 19047163
[TBL] [Abstract][Full Text] [Related]
33. Treatment of hepatocellular carcinoma with a GPC3-targeted bispecific T cell engager.
Bi Y; Jiang H; Wang P; Song B; Wang H; Kong X; Li Z
Oncotarget; 2017 Aug; 8(32):52866-52876. PubMed ID: 28881778
[TBL] [Abstract][Full Text] [Related]
34. Mechanisms and Clinical Trials of Hepatocellular Carcinoma Immunotherapy.
Huang SL; Wang YM; Wang QY; Feng GG; Wu FQ; Yang LM; Zhang XH; Xin HW
Front Genet; 2021; 12():691391. PubMed ID: 34306031
[TBL] [Abstract][Full Text] [Related]
35. Glypican-3-Targeted
Labadie KP; Hamlin DK; Kenoyer A; Daniel SK; Utria AF; Ludwig AD; Kenerson HL; Li L; Sham JG; Chen DL; Orozco JJ; Yeung RS; Orvig C; Li Y; Wilbur DS; Park JO
J Nucl Med; 2022 Jul; 63(7):1033-1038. PubMed ID: 34772791
[TBL] [Abstract][Full Text] [Related]
36. [Usefulness of a novel oncofetal antigen, glypican-3, for diagnosis and immunotherapy of hepatocellular carcinoma].
Nishimura Y; Nakatsura T; Senju S
Nihon Rinsho Meneki Gakkai Kaishi; 2008 Oct; 31(5):383-91. PubMed ID: 18974622
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of circumferential cell surface immunoreactivity of glypican-3 in hepatocellular carcinoma.
Yorita K; Takahashi N; Takai H; Kato A; Suzuki M; Ishiguro T; Ohtomo T; Nagaike K; Kondo K; Chijiiwa K; Kataoka H
Liver Int; 2011 Jan; 31(1):120-31. PubMed ID: 20964802
[TBL] [Abstract][Full Text] [Related]
38. Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report.
Sun H; Xing C; Jiang S; Yu K; Dai S; Kong H; Jin Y; Shan Y; Yang W; Wang Z; Xiao J; Wang H; Wang W; Li Z; Shi K
Front Immunol; 2022; 13():963031. PubMed ID: 36059488
[TBL] [Abstract][Full Text] [Related]
39. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival.
Sawada Y; Yoshikawa T; Nobuoka D; Shirakawa H; Kuronuma T; Motomura Y; Mizuno S; Ishii H; Nakachi K; Konishi M; Nakagohri T; Takahashi S; Gotohda N; Takayama T; Yamao K; Uesaka K; Furuse J; Kinoshita T; Nakatsura T
Clin Cancer Res; 2012 Jul; 18(13):3686-96. PubMed ID: 22577059
[TBL] [Abstract][Full Text] [Related]
40. Derivation and Preclinical Characterization of CYT-303, a Novel NKp46-NK Cell Engager Targeting GPC3.
Arulanandam A; Lin L; Chang HM; Cerutti M; Choblet S; Gao P; Rath A; Bensussan A; Kadouche J; Teper D; Mandelboim O; Li W
Cells; 2023 Mar; 12(7):. PubMed ID: 37048069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
